Navigation Links
Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
Date:11/5/2010

SAN DIEGO, Nov. 5, 2010 /PRNewswire/ -- Ambit Biosciences Corporation (“Ambit”), announced today that it has filed a registration statement with the Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of shares of its common stock.  The number of shares to be offered and the price range for the offering have not yet been determined. All shares of the common stock to be sold in the offering will be offered by Ambit.

J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering, and Leerink Swann LLC and Wedbush Securities Inc. and are acting as co-managers.  This offering will be made only by means of a prospectus.  When available, copies of the preliminary prospectus relating to this offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by calling (866) 803-9204, and Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York 10010, or by calling (800) 221-1037.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About AmbitAmbit Biosciences Corporation is a biotechnology company engaged in discovering, developing and commercializing targeted small molecule therapeutics for the treatment of cancer.  Contact:Alan Fuhrman

Chris Morl

Carol RuthChief Financial Officer

Chief Operating Officer

The Ruth GroupAmbit Biosciences

Ambit Biosciences

(646) 536-7004(858) 334-2133

(858) 334-2134

cruth@theruthgroup.com afuhrman@ambitbio.com

cmorl@ambitbio.com
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
2. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
3. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
4. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
5. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
6. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
7. Neurocrine Biosciences Reports Third Quarter 2010 Results
8. Neurocrine Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
9. Adeona CEO to Provide Keynote Address at the 2010 MichBio Expo & Conference Emerging Biosciences Showcase
10. Accium BioSciences Announces $99 Sample Pricing for Its Accelerator Mass Spectrometry (AMS) Measurement Service
11. 3-V Biosciences Appoints Merdad V. Parsey, MD, PhD, as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... Pharmaceuticals Inc. (NASDAQ: SGYP ), Novo Nordisk A/S ... SCMP ), and Pernix Therapeutics Holdings Inc. (NASDAQ: ... which fell on Thursday, January 19 th , 2017, finishing ... NYSE Health Care Index dropped over 0.7%, while shares of ...
(Date:1/20/2017)... Jan. 20, 2017  Palladian Health, a leading ... the launch of an opioid management program which ... opioids and helps stem the growing tide of ... to treat chronic non-cancer pain (back pain, neck ... and lack of evidence regarding long-term effectiveness. ...
(Date:1/20/2017)... 2017 Entscheidung fällt ... Die internationale humanitäre Stadt soll um knapp ... Seine Hoheit Scheich Muhammad bin ... Herrscher von Dubai , hat den ... (International Humanitarian City IHC) zu verdreifachen, um den Betrieb ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... 2017 , ... Doctor C LLC, a company based out of Arizona that ... continue the marketing and distribution of its product, The Right C. , The Right ... absorption than traditional vitamin C supplements. At the trade show, Doctor C had the ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company based ... school-aged children since the holiday season. , “It happens every year around this ... hugs and taking photos, which is the head-to-head gateway that lice need to spread.” ...
(Date:1/20/2017)... ... , ... International Protein, a company based out of Australia that focuses on ... ECRM trade show in Hilton Head, SC. , International Protein was founded by ... line of products that would elevate her fitness regime. At this ECRM trade show, ...
(Date:1/20/2017)... Viejo, California (PRWEB) , ... January 20, 2017 , ... ... easy to use inside of Final Cut Pro X," said Christina Austin - CEO ... on the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light ...
(Date:1/20/2017)... ... ... “Mary Magdalene: Grace is Greater than Sin”: a unique and memorable piece ... “Mary Magdalene: Grace is Greater than Sin” is the creation of published author, Brenda ... women who had little knowledge of the female characters portrayed in the Holy Bible. ...
Breaking Medicine News(10 mins):